Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (PFGTF) ) has provided an announcement.
Pacific Edge Limited announced significant achievements for the 2025 financial year, including a ‘Grade A’ evidence rating for its Cxbladder Triage test by the American Urological Association and a proposed price increase by the US Centers for Medicare & Medicaid Services for its Cxbladder Triage Plus test. These milestones are expected to enhance the company’s market position and revenue growth, particularly in the US, despite challenges with Medicare coverage. Additionally, the company is undertaking a capital raising initiative to support its financial position, with plans to raise up to $21 million through a placement and retail offer. Shareholders will vote on these matters at the upcoming Annual Shareholders’ Meeting.
More about Pacific Edge Limited
Pacific Edge Limited operates in the healthcare industry, focusing on diagnostic tests for cancer detection. Its primary product, Cxbladder, is a non-invasive test for bladder cancer, and the company has a significant market focus in the United States.
For detailed information about PFGTF stock, go to TipRanks’ Stock Analysis page.